| Miller JS, McCullar V, Punzel M, Lemischka IR, Moore KA. Single adult human CD34+/Lin-/CD38- progenitors give rise to NK cells, B-lineage cells, dendritic cells and myeloid cells. Blood 1999; 93: 96-106. Miller JS, Cervenka T, Lund J, Okazaki IJ, Moss J. Purine metabolites suppress proliferation of human natural killer cells through a lineage specific P2 purine receptor. J Immunology 1999; 162: 7376-7382. Cooley S, Burns LJ, Miller JS: Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology 1999; 27: 1533-1541. Lickliter JD, Kratzke RA, Nguyen FL, Niehans GA, Miller JS: Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. Experimental Hematology 1999; 27: 1519-1527. Burns LJ, Weisdorf DJ, DeFor TE, Repka TL, Ogle KM, Hummer C, Miller JS: Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with IL-2 plus G-CSF in patients with advanced breast cancer. Experimental Hematology 2000; 28: 96-103. Toor AA, Lund TC, Miller JS. T-Cell Factor-1 (TCF-1) Expression During Human NK Cell Development and in Circulating CD56+bright NK Cells. Exp Hematology 2001; 29: 499-506. Miller JS, McCullar V. Human NK cells with polyclonal lectin and immunoglobulin receptors develop from single hemtopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 2001; 98:705-713.. Miller JS. The biology of natural killer cells in cancer, infection and pregnancy. Exp Hem 2001; 29:1157-68. Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, Weisdorf DJ. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001; 110:339-46. Chiorean EG, Miller JS. The biology of natural killer cells and implications for therapy of human disease. J Hematother & Stem Cell Res 2001; 10:451-63. Nakajima H, Zhao R, Ward J, Dolan M, Hirsch B, Miller JS: The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase CML patients. J. Immunology 2002; 168:643-650. Orchard PJ, Blazar BR, Burger S, Levine B, Basso L, Nelson DM, Gordon K, McIvor RS, Wagner JE, Miller JS. Clinical-scale selection oa anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Human Gene Therapy 2002; 13:979-88. Davies SM, Ruggieri L, Defor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100:3825-27. Barker JN, Davies SM, DeFor TE, Burns LJ, McGlave PB, Miller JS, Weisdaorf DJ. Determinants of survival after human leukocyte antigen-matched unrelated donor bone marrow transplantation in adults. British J. Haematology 2002; 118:101-7. Feltis BA. Miller JS. Sahar DA. Kim AS. Saltzman DA. Leonard AS. Wells CL. Sielaff TD. Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer. Journal of Surgical Research 2002; 107:101-7. Burns LJ, Weisdorf DW, Vesole D, Repka T, Blazar BR, Burger SR, Panoskalysis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS: IL-2 Based Immunotherapy after Autologous Transplantation for Lymphoma and Breast Cancer Induces Immune Activation and Cytokine Release: A Phase I/II Trial. Bone Marrow Transplantation 2003; 32:177-186. Sachdev, D, Li, S, Hartell, JS, Fujita-Yamaguchi, Y, Miller, JS, and Yee, D. A chimeric single-chain antibody against the type I insulin-like growth factor receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Research 2003; 63:627-635. Chiorean EG, Dylla, SJ, Olsen K, Dylla S, Lenvik T, Miller JS: BCR/ABL Alters the Function of NK Cells and the Acquisition of Killer Immunoglobulin-like Receptors (KIR). Blood 2003; 101:3527-33. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102:1915-9. Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR , McGlave PB, Burns LJ, Charlotte Brown C, Miller JS: Donor Chimerism does not Predict Response to DLI for Relapsed CML after Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation 2004; 10:171-77. Chen W, Chan ASH, Dawson AJ, Liang X, Blazar BR, Miller JS: FLT3-ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and NK-cell function. Biology of Blood and Marrow Transplantation 2005; 11:23-34. Miller JS. How killers kill. Blood. 2008; 112:213. Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol. 2008; 31:173-181. McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE, Miller JS. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol. 2008; 36:598-608. Cichocki F, Hanson RJ, Lenvik T, Pitt M, McCullar V, Li H, Anderson SK, Miller JS. The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood. 2008 Nov 5; [Epub ahead of print]. Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transplant. 2009 Jan 12. [Epub ahead of print] PMID: 19139736 Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681 Bachanova V, McCullar V, Lenvik T, Wangen R, Peterson KA, Ankarlo DE, Panoskaltsis-Mortari A, Wagner JE, Miller JS. Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions. Biol Blood Marrow Transplant. 2009; 15:183-94. PMID: 19167678 Miller JS. Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential? Cytotherapy. 2009 Apr 6:1-2. [Epub ahead of print] PMID: 19347766 Hummon D, Zantek ND, Sumstad D, Miller JS, McKenna DH. Transfusion-associated graft-versus-host disease: a perspective from a cell therapy laboratory. Transfusion. 2009;49:1018-9. PMID: 19426202 Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009; 27(22): 3634-41. PMID: 19581540 Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 5;114(19):4293-9. Porter DL, Hexner EO, Cooley S, Miller JS. Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009;144:497-537. Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young JA, Weisdorf DH, Cooley S, Miller JS, Verneris MR. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010 Feb;16(2):215-22. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 2009 Oct;147(2):185-91 Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S57-63. Anderson E, Grzywacz B, Wang H, Wang T, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR. Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. Blood. 2009 Nov 19;114(21):4753-4; author reply 4754-5. Cichocki F, Miller JS. In vitro development of human Killer-Immunoglobulin Receptor-positive NK cells. Methods Mol Biol. 2010;612:15-26. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010 May;16(5):612-21. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant. 2010 May;16(5):565-86. Tomblyn M, Young JA, Haagenson MD, Klein JP, Trachtenberg EA, Storek J, Spellman SR, Cooley S, Miller JS, Weisdorf DJ; CIBMTR Infection and Immune Reconstitution Working Committee. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant. 2010 Aug;16(8):1155-61. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):563-4. Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011 Jan;46(1):20-6. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010 Oct 7;116(14):2411-9. Cichocki F, Lenvik T, Sharma N, Yun G, Anderson SK, Miller JS. Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells. J Immunol. 2010 Aug 15;185(4):2009-12. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010 Nov;59(11):1739-44. Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010 Dec;59(12):1877-84. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. Biol Blood Marrow Transplant. 2011 Jun;17(6):831-40. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011 Jan;13(1):98-107. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011 Jan 20;117(3):1061-70. Grzywacz B, Kataria N, Kataria N, Blazar BR, Miller JS, Verneris MR. Natural killer-cell differentiation by myeloid progenitors. Blood. 2011 Mar 31;117(13):3548-58. Pyo CW, Guethlein LA, Vu Q, Wang R, Abi-Rached L, Norman PJ, Marsh SG, Miller JS, Parham P, Geraghty DE. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One. 2010 Dec 29;5(12):e15115. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54. Tang Q, Ahn YO, Southern P, Blazar BR, Miller JS, Verneris MR. Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. Blood. 2011 Apr 14;117(15):4052-5. Cichocki F, Miller JS, Anderson SK. Killer immunoglobulin-like receptor transcriptional regulation: a fascinating dance of multiple promoters. J Innate Immun. 2011;3(3):242-8. Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. 2011 Jun;11(6):1148-57. Henson MS, Curtsinger JM, Larson VS, Klausner JS, Modiano JF, Mescher MF, Miller JS. Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma. Vet Comp Oncol. 2011 Jun;9(2):95-105. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR. Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity. Sci Transl Med. 2011 May 18;3(83):83ra41. Brunstein CG, Noreen H, Defor TE, Maurer D, Miller JS, Wagner JE. Anti-HLA Antibodies in Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2011 May 3. [Epub ahead of print] Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma. 2011 Jun 12. [Epub ahead of print]
|
